BV Partner Treatment: The Science Behind Treating Men to Prevent Recurring BV

BV Partner Treatment: The Science Behind Treating Men to Prevent Recurring BV

If you're reading this, you've likely dealt with the frustrating cycle of recurring Bacterial Vaginosis (BV). Despite completing your antibiotics, the symptoms come back — the odor, the discharge, the discomfort. For decades, the medical community didn't have a good answer for why BV recurs so frequently. A landmark clinical trial published in 2025 may have finally cracked the code: the answer involves treating your male partner.

The Problem: Why Does BV Keep Coming Back?

BV occurs when the protective Lactobacillus bacteria in the vagina are displaced by an overgrowth of anaerobic bacteria, most notably Gardnerella vaginalis. Standard treatment with antibiotics like Metronidazole effectively clears these bacteria from the vagina — but here's the catch:

Researchers at the Melbourne Sexual Health Centre discovered that BV-associated bacteria, including Gardnerella vaginalis, can colonize the penile skin and urethra of male sexual partners without causing any symptoms in the man. During subsequent sexual intercourse, these bacteria transfer back to the woman's vagina, disrupting the newly restored microbiome and triggering BV all over again.

This "ping-pong" effect of bacterial transmission between partners is what makes BV one of the most common recurring vaginal conditions. Previous approaches only treated the woman, leaving a reservoir of bacteria on the male partner's body.

Is partner treatment right for you?

Complete our quick clinical screening to see if your male partner is eligible for concurrent BV partner therapy.

Start Screening

The Breakthrough: The StepUp Trial

The StepUp trial (also known as StePHanie) was a multi-year randomized controlled trial that enrolled couples where the woman had BV and was in a monogamous relationship with a male partner. The study compared two groups:

The results were so compelling that the trial's independent data and safety monitoring board recommended stopping the trial early — a rare event that occurs only when there is overwhelming evidence of benefit and it would be unethical to continue assigning patients to the control group.

What Does the Treatment Involve?

The partner treatment protocol involves two antibiotics used simultaneously for 7 days:

1. Oral Metronidazole (500mg oral tablet): Taken by mouth twice daily for 7 days. This targets bacteria within the urethra and systemically. Critical: All alcohol must be avoided during treatment and for 48 hours after the last dose.
2. Topical Clindamycin 2% Cream: Applied to the head (glans) of the penis and upper shaft twice daily for 7 days. If uncircumcised, the cream should also be applied under the foreskin. This directly targets bacteria residing on the penile skin surface.

The key insight from the StepUp trial was that both oral AND topical treatment are necessary. Earlier studies that only used oral antibiotics for male partners showed limited benefit because they failed to clear bacteria from the penile skin surface.

Who Is This For?

BV partner therapy is specifically designed for:

• Male partners in a current, ongoing sexual relationship with a woman diagnosed with BV
• Partners who are asymptomatic — meaning they have NO active genital or urinary symptoms
• Patients who can commit to avoiding alcohol for the full treatment course plus 48 hours

This treatment is NOT appropriate for men with active genital symptoms (discharge, sores, pain), suspected STI exposure, liver disease, or those allergic to Metronidazole or Clindamycin.

If you and your partner are tired of the BV recurrence cycle, concurrent partner therapy may be the missing piece. At Herexa Health, we bring this cutting-edge, evidence-based treatment directly to you — privately, conveniently, and without the need for an in-person visit.